Core Viewpoint - 康基医疗 reported a revenue of RMB 497 million for the six months ending June 30, 2025, representing an 8.3% increase compared to the same period in 2024, with a net profit attributable to shareholders of RMB 266 million [1] Group 1: Financial Performance - The company achieved a revenue of RMB 497 million for the first half of 2025, marking an 8.3% growth year-on-year [1] - The net profit attributable to the parent company reached RMB 266 million during the same period [1] Group 2: Product Development and Innovation - The company placed significant emphasis on product research and development, planning to continuously increase R&D expenditure [2] - The product portfolio includes a wide range of minimally invasive surgical devices, instruments, and consumables, providing a comprehensive one-stop solution for minimally invasive surgery [2] - Several products received approval from the National Medical Products Administration (NMPA) in China, including the 4K3D fluorescence endoscope imaging system and other surgical instruments [2] - The company has obtained 21 new patent authorizations during the reporting period, while a subsidiary secured 23 new patents [1][2] - Innovative products such as absorbable knotless sutures and ligation clips are being promoted for clinical market applications, enhancing surgical efficiency [2]